Q-omics provides the consensus-scored ENTPD3 profile across patient tissues and cancer cell-line models. ENTPD3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, ENTPD3 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ENTPD3 RNA expression shows 20,284 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight STAD, KIRC, and GBM as cancer lineages where ENTPD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ENTPD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ENTPD3 survival associations across molecular data types. ENTPD3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ENTPD3 RNA expression–survival associations across cancer types. High ENTPD3 expression shows unfavorable associations in STAD, UVM and ACC, but favorable associations in UCEC, BRCA and COAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for ENTPD3 RNA expression.
This table summarizes ENTPD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ENTPD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ENTPD3 shows lower tumor expression in KIRC, KICH, KIRP, COAD and STAD and higher tumor expression in UCEC. The KIRC box plot shows higher ENTPD3 RNA expression in normal versus tumor tissue (log2 FC = −1.742, t-test p < 0.001).
This table shows molecular features associated with ENTPD3 in patient tissues and cancer cell lines. In patient samples, ENTPD3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ENTPD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and URINARY_TRACT.
